



Call for R&I Flagship proposals responding to CARE missions 4 and 5



Contents

Introduction:	1
Objective:.....	1
Scope:.....	1
Project Duration:	1
Funding:.....	2
Eligibility:.....	2
Submission Guidelines:.....	2
Evaluation Process:.....	2
Important Dates:	2

Introduction

We are pleased to announce the second stage of new calls in the context of the Gulbenkian Institute for Molecular Medicine (GIMM)'s Clinical and Translational research branch: CARE.

CARE's major aim is to facilitate and expedite the early adoption of innovation in healthcare through ideas, technologies, products and services, serving as an independent platform for informed dialogue and collaboration between all stakeholders.

Following the definition of new missions resulting from the first stage of the CARE 2024 call, we now invite submissions for **funded CARE R&I Flagships** responding to those Missions.

Objective

R&I flagships are expected to develop and implement a specific solution with measurable outcomes, demonstrated critical mass, and within a tangible timeframe. Multiple flagships responding to the same mission may be submitted.

Scope

R&I Flagships must respond directly to one of the following missions:

- **CARE Mission 4: Boost sepsis recovery with faster diagnosis and personalized medicine.**
For example, reducing the mortality rate to <20% of in-hospital cases.
- **CARE Mission 5: Faster diagnosis of a rare genetic disease.**
For example, reducing diagnosis to <2 years from symptom onset, improving health outcomes.

Project Duration

Up to 3 years

Funding

Successful proposals will be selected for financial support. The total available funding for the call is 600,000 EUR, with a guide value of anywhere between 5,000 and 200,000 EUR per flagship project. These funds are intended for allocation towards *Human Resources (GIMM)*, *Missions (Travel)*, *Equipment*, *Use of GIMM Facilities (costed as internal user)*, *Other Goods and services*, *Patent registration*, *Demonstration*, *Promotion and Publication and/or Subcontracts* as required. Apportionment of these funds will be contingent upon the merit and relevance of each project proposal, with express justification. Cost-effectiveness will be included in the evaluation.

Note: funds will not be transferred directly to another entity. Personnel must be hired through GIMM. Applicants should aim to make use of GIMM facilities. IP will be shared with GIMM (see specific section of application form for foreground and background IP).

Eligibility

Flagship proposals are invited from any member of the Gulbenkian Institute for Molecular Medicine (GIMM) or from a team including a collaborating GIMM member, at any career stage, independently of whether or not they submitted a mission proposal to the first-stage call.

Priority will be given to teams also including a healthcare professional.

Teams will be required to declare that the described project work is not already funded by another source.

Submission Guidelines

Interested people are invited to submit their proposals for Flagships by **9 March 2025 by email to care@gimm.pt**, attaching the **2 completed templates (1 pdf + 1 excel file)**.

[Templates are provided online here.](#)

Evaluation Process

The evaluation process will include the following steps:

1. Proposal documents evaluation
Submissions will be scored by invited evaluators against the following criteria: *Flagship Overall Design, Feasibility, Innovation, Impact, Responsible Research and Innovation, Team fit*. The budget and workplan will be analysed by GIMM-CARE operational team.
In the event of a tie, projects that show cost efficiency will be given priority.
2. Pre-selection interview with field-specific experts.
3. Grant agreement negotiation.

Important Dates

- Opening of second stage call: 7th February 2025
- Closing of second stage call: 9th March 2025
- Communication of results: 30th April 2025
- Flagships project start dates: from May 2025

For any questions, please contact: care@gimm.pt